The FDA expanded Wilate's approval for routine prophylaxis to reduce bleeding episodes in children aged younger than 6 years with von Willebrand disease, supported by phase 3 WIL-33 data showing low annualized bleeding rates and favorable tolerability.
FDA Expands Wilate Approval for Routine Prophylaxis in Children Younger Than 6 With von Willebrand Disease
